Financial reports
10-K
2023 FY
Annual report
21 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
20-F
2022 FY
Annual report (foreign)
7 Mar 23
20-F
2021 FY
Annual report (foreign)
10 Mar 22
20-F
2020 FY
Annual report (foreign)
4 Mar 21
20-F/A
2019 FY
Annual report (foreign) (amended)
30 Jun 20
20-F
2019 FY
Annual report (foreign)
3 Mar 20
20-F
2019 Q1
Annual report (foreign)
25 Feb 19
20-F
2018 FY
Annual report (foreign)
23 Nov 18
Current reports
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
21 Mar 24
8-K/A
Results of Operations and Financial Condition
15 Mar 24
8-K
Results of Operations and Financial Condition
14 Mar 24
8-K
Regulation FD Disclosure
13 Feb 24
8-K
Autolus Announces Pricing of Underwritten Offering
8 Feb 24
8-K
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
8 Feb 24
8-K
Regulation FD Disclosure
26 Jan 24
8-K
Departure of Directors or Certain Officers
10 Jan 24
8-K
Departure of Directors or Certain Officers
22 Dec 23
8-K
Regulation FD Disclosure
11 Dec 23
Registration and prospectus
D
Exempt offering of security
23 Feb 24
424B5
Prospectus supplement for primary offering
9 Feb 24
S-3ASR
Automatic shelf registration
7 Feb 24
S-8
Registration of securities for employees
3 Nov 23
S-8
Registration of securities for employees
7 Aug 23
F-6EF
Automatic registration for ADRs (foreign)
1 Mar 23
424B5
Prospectus supplement for primary offering
9 Dec 22
424B5
Prospectus supplement for primary offering
8 Dec 22
424B3
Prospectus supplement
18 May 22
F-3
Shelf registration (foreign)
3 May 22
Proxies
No filings
Other
EFFECT
Notice of effectiveness
18 May 22
CORRESP
Correspondence with SEC
13 May 22
UPLOAD
Letter from SEC
9 May 22
EFFECT
Notice of effectiveness
29 Apr 22
CORRESP
Correspondence with SEC
26 Apr 22
UPLOAD
Letter from SEC
20 Apr 22
EFFECT
Notice of effectiveness
19 Aug 21
CORRESP
Correspondence with SEC
16 Aug 21
UPLOAD
Letter from SEC
12 Aug 21
UPLOAD
Letter from SEC
9 Jul 20
Ownership
SC 13D/A
Kellnerova Renata
25 Mar 24
SC 13D
BioNTech SE
21 Feb 24
SC 13G/A
Paradigm Biocapital Advisors LP
14 Feb 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
Syncona Portfolio Ltd
13 Feb 24
SC 13G/A
Tetragon Financial Management LP
31 Jan 24
SC 13G
Paradigm Biocapital Advisors LP
10 Jul 23
SC 13G
Tetragon Financial Management LP
20 Mar 23
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 23